Aclaris Therapeutics, Inc.
ACRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $19 | $31 | $30 | $7 |
| % Growth | -40.1% | 5% | 340.1% | – |
| Cost of Goods Sold | $3 | $18 | $12 | $5 |
| Gross Profit | $16 | $13 | $18 | $2 |
| % Margin | 85.1% | 42.1% | 59.8% | 30.3% |
| R&D Expenses | $34 | $98 | $78 | $44 |
| G&A Expenses | $22 | $31 | $25 | $24 |
| SG&A Expenses | $22 | $31 | $25 | $24 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $102 | -$19 | $5 | $24 |
| Operating Expenses | $158 | $111 | $108 | $92 |
| Operating Income | -$142 | -$97 | -$90 | -$90 |
| % Margin | -758.2% | -311.6% | -302% | -1,327.1% |
| Other Income/Exp. Net | $10 | $9 | $3 | -$1 |
| Pre-Tax Income | -$132 | -$89 | -$87 | -$91 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$132 | -$88 | -$87 | -$91 |
| % Margin | -705.5% | -283.1% | -292.1% | -1,344% |
| EPS | -1.71 | -1.27 | -1.33 | -1.6 |
| % Growth | -34.6% | 4.5% | 16.9% | – |
| EPS Diluted | -1.71 | -1.27 | -1.33 | -1.6 |
| Weighted Avg Shares Out | 77 | 70 | 65 | 57 |
| Weighted Avg Shares Out Dil | 77 | 70 | 65 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$52 | -$115 | -$84 | -$64 |
| % Margin | -276.3% | -369.5% | -283.5% | -953.4% |